Targeting the extracellular signature of metastatic colorectal cancers

Expert Opinion on Therapeutic Targets

Volumn 13, Issue 3, 2009, Pages 363-379

  Marchi, Serena ^a,b   Arap, Wadih ^b   Pasqualini, Renata ^c  

^a CANDIOLO CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

Metastatic colorectal cancer; Phage display; Targeted therapy

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CELL PROTEIN; CETUXIMAB; DOCETAXEL; DOXORUBICIN; ERLOTINIB; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MEMBRANE PROTEIN; MITOXANTRONE; NANOPARTICLE; ORZEL; OXALIPLATIN; PANITUMUMAB; TRASTUZUMAB; ANTINEOPLASTIC AGENT;

BLEEDING; CANCER THERAPY; CLINICAL TRIAL; COLORECTAL CANCER; DIAGNOSTIC PROCEDURE; DIGESTIVE SYSTEM PERFORATION; DRUG DELIVERY SYSTEM; HUMAN; HYPERTENSION; LIVER METASTASIS; MEDLINE; METASTASIS; METHODOLOGY; NANOTECHNOLOGY; REVIEW; SYSTEMATIC REVIEW; THROMBOEMBOLISM; ANIMAL; COLORECTAL TUMOR; PATHOPHYSIOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; NANOTECHNOLOGY; NEOPLASM METASTASIS;

EID: 65549142182     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728220902762910     Document Type: Review

References (153)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008 ; 58 (2): 71-96
2. Midgley R, Kerr D. Colorectal cancer. Lancet 1999 ; 353 (9150): 391-399 (Pubitemid 29088178)
3. Wolpin BM, Mayer RJ. Systemic treatment of colorectal cancer. Gastroenterology 2008 ; 134 (5): 1296-1310 (Pubitemid 351615376)
4. Tomlinson JS, Jarnagin WR, DeMatteo RP, et al. Actual 10-year survival after resection of colorectal liver metastases defi nes cure. J Clin Oncol 2007 ; 25 (29): 4575-4580 (Pubitemid 350035315)
5. Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005 ; 352 (26): 2696-2704 (Pubitemid 41007824)
6. Rothenberg ML. Irinotecan (CPT-11): recent developments and future directions - colorectal cancer and beyond. Oncologist 2001 ; 6 (1): 66-80 (Pubitemid 32155817)
7. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fl uorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004 ; 350 (23): 2343-2351 (Pubitemid 38702845)
8. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fl uorouracil and leucovorin: an active regimen for fi rst-line metastatic colorectal cancer. J Clin Oncol 2005 ; 23 (15): 3502-3508 (Pubitemid 46243494)
9. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007 ; 25 (12): 1539-1544 (Pubitemid 46733080)
10. Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin and fl uoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol 2008 ; 26 (21): 3523-3529
11. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as fi rst-line therapy in metastatic colorectal cancer: a randomized Phase III study. J Clin Oncol 2008 ; 26 (12): 2013-2019
12. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004 ; 351 (4): 337-345 (Pubitemid 38944402)
13. Giusti RM, Shastri KA, Cohen MH, et al. FDA drug approval summary: panitumumab (Vectibix). Oncologist 2007 ; 12 (5): 577-583 (Pubitemid 350012121)
14. de Gramont A, Bosset JF, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fl uorouracil bolus with bimonthly high-dose leucovorin and fl uorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997 ; 15 (2): 808-815 (Pubitemid 27074252)
15. Petrelli N, Douglass HO Jr, Herrera L, et al. The modulation of fl uorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized Phase III trial. Gastrointestinal Tumor Study Group. J Clin Oncol 1989 ; 7 (10): 1419-1426 (Pubitemid 19245111)
16. Poon MA, O'Connell MJ, Moertel CG, et al. Biochemical modulation of fl uorouracil: evidence of signifi cant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989 ; 7 (10): 1407-1418 (Pubitemid 19245110)
17. Compton C, Fenoglio-Preiser CM, Pettigrew N, Fielding LP. American joint committee on cancer prognostic factors consensus conference: colorectal working group. Cancer 2000 ; 88 (7): 1739-1757 (Pubitemid 30183160)
18. Greene FL, Stewart AK, Norton HJ. A new TNM staging strategy for node-positive (stage III) colon cancer: an analysis of 50,042 patients. Ann Surg 2002 ; 236 (4): 416-421
19. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American joint committee on cancer sixth edition staging. J Natl Cancer Inst 2004 ; 96 (19): 1420-1425 (Pubitemid 39429665)
20. Compton CC, Greene FL. The staging of colorectal cancer: 2004 and beyond. CA Cancer J Clin 2004 ; 54 (6): 295-308
21. Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fl uorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004 ; 22 (7): 1209-1214 (Pubitemid 41079833)
22. Heidelberger C, Chaudhuri NK, Danneberg P, et al. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature 1957 ; 179 (4561): 663-666
23. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fl uorouracil with or without oxaliplatin as fi rst-line treatment in advanced colorectal cancer. J Clin Oncol 2000 ; 18 (16): 2938-2947 (Pubitemid 30644117)
24. Zhang ZG, Harstrick A, Rustum YM. Modulation of fl uoropyrimidines: role of dose and schedule of leucovorin administration. Semin Oncol 1992 ; 19 (2 Suppl 3): 10-15
25. Thirion P, Michiels S, Pignon JP, et al. Modulation of fl uorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 2004 ; 22 (18): 3766-3775
26. Efficacy of intravenous continuous infusion of fl uorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis group in cancer. J Clin Oncol 1998 ; 16 (1): 301-308
27. Pentheroudakis G, Twelves C. The rational development of capecitabine from the laboratory to the clinic. Anticancer Res 2002 ; 22 (6B): 3589-3596 (Pubitemid 36132834)
28. Van Cutsem E, Hoff PM, Harper P, et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated effi cacy data and novel analyses from two large, randomised, Phase III trials. Br J Cancer 2004 ; 90 (6): 1190-1197 (Pubitemid 38496812)
29. Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fl uorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large Phase III study. J Clin Oncol 2001 ; 19 (21): 4097-4106 (Pubitemid 33049527)
30. Wereldsma JC, Bruggink ED, Meijer WS, et al. Adjuvant portal liver infusion in colorectal cancer with 5-fl uorouracil/heparin versus urokinase versus control. Results of a prospective randomized clinical trial (colorectal adenocarcinoma trial I). Cancer 1990 ; 65 (3): 425-432
31. Taylor I, Machin D, Mullee M, et al. A randomized controlled trial of adjuvant portal vein cytotoxic perfusion in colorectal cancer. Br J Surg 1985 ; 72 (5): 359-363 (Pubitemid 15034705)
32. Beart RW Jr, Moertel CG, Wieand HS, et al. Adjuvant therapy for resectable colorectal carcinoma with fl uorouracil administered by portal vein infusion. A study of the Mayo clinic and the North central Cancer Treatment Group. Arch Surg 1990 ; 125 (7): 897-901
33. Wolmark N, Rockette H, Wickerham DL, et al. Adjuvant therapy of Dukes' A, B, and C adenocarcinoma of the colon with portal-vein fl uorouracil hepatic infusion: preliminary results of National Surgical Adjuvant Breast and Bowel Project Protocol C-02. J Clin Oncol 1990 ; 8 (9): 1466-1475 (Pubitemid 20301177)
34. Swiss Group for Clinical Cancer Research (SAKK). Long-term results of single course of adjuvant intraportal chemotherapy for colorectal cancer. Swiss Group for Clinical Cancer Research (SAKK). Lancet 1995 ; 345 (8946): 349-353
35. Fielding LP, Hittinger R, Grace RH, Fry JS. Randomised controlled trial of adjuvant chemotherapy by portal-vein perfusion after curative resection for colorectal adenocarcinoma. Lancet 1992 ; 340 (8818): 502-506
36. Liver Infusion Meta-analysis Group. Portal vein chemotherapy for colorectal cancer: a meta-analysis of 4000 patients in 10 studies. J Natl Cancer Inst 1997 ; 89 (7): 497-505 (Pubitemid 27147266)
37. Mathijssen RH, van Alphen RJ, Verweij J, et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001 ; 7 (8): 2182-2194 (Pubitemid 32751614)
38. Wasserman E, Myara A, Lokiec F, et al. Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports. Ann Oncol 1997 ; 8 (10): 1049-1051 (Pubitemid 27475739)
39. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fl uorouracil compared with fl uorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000 ; 355 (9209): 1041-1047 (Pubitemid 30162806)
40. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fl uorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000 ; 343 (13): 905-914 (Pubitemid 30727802)
41. Fuchs C, Mitchell EP, Hoff PM. Irinotecan in the treatment of colorectal cancer. Cancer Treat Rev 2006 ; 32 (7): 491-503 (Pubitemid 44478737)
42. Raymond E, Chaney SG, Taamma A, Cvitkovic E. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 1998 ; 9 (10): 1053-1071 (Pubitemid 28518143)
43. Raymond E, Faivre S, Woynarowski JM, Chaney SG. Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 1998 ; 25 (2 Suppl 5): 4-12 (Pubitemid 28248696)
44. Becouarn Y, Ychou M, Ducreux M, et al. Phase II trial of oxaliplatin as fi rst-line chemotherapy in metastatic colorectal cancer patients. Digestive group of French federation of cancer centers. J Clin Oncol 1998 ; 16 (8): 2739-2744
45. Diaz-Rubio E, Sastre J, Zaniboni A, et al. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a Phase II multicentric study. Ann Oncol 1998 ; 9 (1): 105-108 (Pubitemid 28125772)
46. Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as fi rst-line treatment of metastatic colorectal cancer. J Clin Oncol 2000 ; 18 (1): 136-147 (Pubitemid 30036347)
47. Rothenberg ML, Oza AM, Bigelow RH, et al. Superiority of oxaliplatin and fl uorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fl uorouracil-leucovorin: interim results of a Phase III trial. J Clin Oncol 2003 ; 21 (11): 2059-2069 (Pubitemid 46606353)
48. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004 ; 22 (2): 229-237 (Pubitemid 41095086)
49. Colucci G, Gebbia V, Paoletti G, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 2005 ; 23 (22): 4866-4875 (Pubitemid 46223991)
50. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971 ; 285 (21): 1182-1186
51. Folkman J, Merler E, Abernathy C, Williams G. Isolation of a tumor factor responsible for angiogenesis. J Exp Med 1971 ; 133 (2): 275-288
52. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003 ; 9 (6): 669-676 (Pubitemid 36749215)
53. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005 ; 438 (7070): 967-974 (Pubitemid 43093963)
54. Berry SR, Van Cutsem E, Kretzschmar A, et al. Final effi cacy results for bevacizumab plus standard fi rst-line chemotherapies in patients with metastatic colorectal cancer: fi rst BEAT [abstract 4025]. J Clin Oncol 2008 ; 26 (Suppl)
55. Grothey A, Sugrue MM, Purdie DM, et al. Bevacizumab beyond fi rst progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 2008 ; 26 (33): 5326-5334
56. Purdie DM, Berlin JD, Flynn PJ, et al. The safety of long-term bevacizumab use: Results from the BRiTE observational cohort study (OCS) [abstract 4103]. J Clin Oncol 2008 ; 26 (Suppl)
57. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 2002 ; 7 (Suppl 4): 2-8 (Pubitemid 34977157)
58. Messersmith WA, Hidalgo M. Panitumumab, a monoclonal anti epidermal growth factor receptor antibody in colorectal cancer: another one or the one? Clin Cancer Res 2007 ; 13 (16): 4664-4666
59. Jonker DJ, O'callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007 ; 357 (20): 2040-2048 (Pubitemid 350106711)
60. Van Cutsem E, Peeters M, Siena S, et al. Open-label Phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007 ; 25 (13): 1658-1664 (Pubitemid 46797944)
61. Van Cutsem E, Lang I, D'haens G, et al. KRAS status and effi cacy in the fi rst-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without Cetuximab: The CRYSTAL experience [abstract 2]. J Clin Oncol 2008 ; 26
62. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab effi cacy in patients with metastatic colorectal cancer. J Clin Oncol 2008 ; 26 (10): 1626-1634
63. Venook AP. Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinoma. Cancer 2005 ; 103 (12): 2435-2446 (Pubitemid 40800520)
64. Saltz LB, Lenz HJ, Kindler HL, et al. Randomized Phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol 2007 ; 25 (29): 4557-4561 (Pubitemid 350035312)
65. Punt CJ, Tol J, Rodenburg CJ, et al. Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG) [abstract LBA4011]. J Clin Oncol 2008 ; 26
66. Hecht JR, Mitchell E, Chidiac T, et al. A randomized Phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2008 , published online Dec 29 2008, doi: 10.1200/JCO.2008.19.8135
67. Lodge JP. Modern surgery for liver metastases. Cancer Imaging 2000 ; 1 : 77-85
68. von Herbay A, Vogt C, Willers R, Haussinger D. Real-time imaging with the sonographic contrast agent SonoVue: differentiation between benign and malignant hepatic lesions. J Ultrasound Med 2004 ; 23 (12): 1557-1568 (Pubitemid 39586861)
69. Schima W, Kulinna C, Langenberger H, Bassalamah A. Liver metastases of colorectal cancer: US, CT or MR? Cancer Imaging 2005 ; 5 Spec No A: S149 -56
70. Weg N, Scheer MR, Gabor MP. Liver lesions: improved detection with dual-detector-array CT and routine 2.5-mm thin collimation. Radiology 1998 ; 209 (2): 417-426 (Pubitemid 28503108)
71. Bennett GL, Petersein A, Mayo-Smith WW, et al. Addition of gadolinium chelates to heavily T2-weighted MR imaging: limited role in differentiating hepatic hemangiomas from metastases. AJR Am J Roentgenol 2000 ; 174 (2): 477-485 (Pubitemid 30067162)
72. Mann GN, Marx HF, Lai LL, Wagman LD. Clinical and cost effectiveness of a new hepatocellular MRI contrast agent, mangafodipir trisodium, in the preoperative assessment of liver resectability. Ann Surg Oncol 2001 ; 8 (7): 573-579 (Pubitemid 32735037)
73. Schima W, Fugger R, Schober E, et al. Diagnosis and staging of pancreatic cancer: comparison of mangafodipir trisodium-enhanced MR imaging and contrast-enhanced helical hydro-CT. AJR Am J Roentgenol 2002 ; 179 (3): 717-724 (Pubitemid 34919588)
74. Hamm B, Staks T, Muhler A, et al. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 1995 ; 195 (3): 785-792
75. Caudana R, Morana G, Pirovano GP, et al. Focal malignant hepatic lesions: MR imaging enhanced with gadolinium benzyloxypropionictetra-acetate (BOPTA)-preliminary results of phase II clinical application. Radiology 1996 ; 199 (2): 513-520 (Pubitemid 26124278)
76. Bird NC, Mangnall D, Majeed AW. Biology of colorectal liver metastases: a review. J Surg Oncol 2006 ; 94 (1): 68-80 (Pubitemid 43967727)
77. Shia J, Klimstra DS, Nitzkorski JR, et al. Immunohistochemical expression of folate receptor α in colorectal carcinoma: patterns and biological signifi cance. Hum Pathol 2008 ; 39 (4): 498-505
78. Zlobec I, Terracciano L, Tornillo L, et al. Role of RHAMM within the hierarchy of well-established prognostic factors in colorectal cancer. Gut 2008 ; 57 (10): 1413-1419
79. Yamada M, Ichikawa Y, Yamagishi S, et al. Amphiregulin is a promising prognostic marker for liver metastases of colorectal cancer. Clin Cancer Res 2008 ; 14 (8): 2351-2356 (Pubitemid 351551067)
80. Oshima T, Akaike M, Yoshihara K, et al. Clinicopathological signifi cance of the gene expression of matrix metalloproteinase-7, insulin-like growth factor-1, insulin-like growth factor-2 and insulin-like growth factor-1 receptor in patients with colorectal cancer: insulin-like growth factor-1 receptor gene expression is a useful predictor of liver metastasis from colorectal cancer. Oncol Rep 2008 ; 20 (2): 359-364
81. Oshima T, Akaike M, Yoshihara K, et al. Overexpression of EphA4 gene and reduced expression of EphB2 gene correlates with liver metastasis in colorectal cancer. Int J Oncol 2008 ; 33 (3): 573-577
82. Paz K, Hadari YR. Targeted therapy of the insulin-like growth factor-1 receptor in cancer. Comb Chem High Throughput Screen 2008 ; 11 (1): 62-69
83. Pasquale EB. Eph-ephrin bidirectional signaling in physiology and disease. Cell 2008 ; 133 (1): 38-52
84. van der Bij GJ, Oosterling SJ, Bogels M, et al. Blocking α2 integrins on rat CC531s colon carcinoma cells prevents operation-induced augmentation of liver metastases outgrowth. Hepatology 2008 ; 47 (2): 532-543 (Pubitemid 351280721)
85. Ma C, Rong Y, Radiloff DR, et al. Extracellular matrix protein βig-h3/TGFBI promotes metastasis of colon cancer by enhancing cell extravasation. Genes Dev 2008 ; 22 (3): 308-321 (Pubitemid 351214273)
86. Nadal C, Maurel J, Gascon P. Is there a genetic signature for liver metastasis in colorectal cancer? World J Gastroenterol 2007 ; 13 (44): 5832-5844
87. Yamasaki M, Takemasa I, Komori T, et al. The gene expression profi le represents the molecular nature of liver metastasis in colorectal cancer. Int J Oncol 2007 ; 30 (1): 129-138
88. Lin HM, Chatterjee A, Lin YH, et al. Genome wide expression profi ling identifi es genes associated with colorectal liver metastasis. Oncol Rep 2007 ; 17 (6): 1541-1549
89. D'Arrigo A, Belluco C, Ambrosi A, et al. Metastatic transcriptional pattern revealed by gene expression profi ling in primary colorectal carcinoma. Int J Cancer 2005 ; 115 (2): 256-262 (Pubitemid 40586734)
90. Yanagawa R, Furukawa Y, Tsunoda T, et al. Genome-wide screening of genes showing altered expression in liver metastases of human colorectal cancers by cDNA microarray. Neoplasia 2001 ; 3 (5): 395-401 (Pubitemid 32988809)
91. Ki DH, Jeung HC, Park CH, et al. Whole genome analysis for liver metastasis gene signatures in colorectal cancer. Int J Cancer 2007 ; 121 (9): 2005-2012 (Pubitemid 47463164)
92. Yoshitake N, Fukui H, Yamagishi H, et al. Expression of SDF-1α and nuclear CXCR4 predicts lymph node metastasis in colorectal cancer. Br J Cancer 2008 ; 98 (10): 1682-1689 (Pubitemid 351684689)
93. Nie L, Wu G, Culley DE, et al. Integrative analysis of transcriptomic and proteomic data: challenges, solutions and applications. Crit Rev Biotechnol 2007 ; 27 (2): 63-75 (Pubitemid 46956894)
94. Yu B, Li SY, An P, et al. Comparative study of proteome between primary cancer and hepatic metastatic tumor in colorectal cancer. World J Gastroenterol 2004 ; 10 (18): 2652-2656 (Pubitemid 39214496)
95. Kang B, Hao C, Wang H, et al. Evaluation of hepatic-metastasis risk of colorectal cancer upon the protein signature of PI3K/AKT pathway. J Proteome Res 2008 ; 7 (8): 3507-3515
96. Varambally S, Yu J, Laxman B, et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 2005 ; 8 (5): 393-406 (Pubitemid 41579834)
97. Habermann JK, Paulsen U, Roblick UJ, et al. Stage-specifi c alterations of the genome, transcriptome, and proteome during colorectal carcinogenesis. Genes Chromosomes Cancer 2007 ; 46 (1): 10-26 (Pubitemid 44772868)
98. Roblick UJ, Hirschberg D, Habermann JK, et al. Sequential proteome alterations during genesis and progression of colon cancer. Cell Mol Life Sci 2004 ; 61 (10): 1246-1255 (Pubitemid 38703754)
99. Zacher AN 3rd, Stock CA, Golden JW 2nd, Smith GP. A new fi lamentous phage cloning vector: fd-tet. Gene 1980 ; 9 (1-2): 127-140
100. Zurita AJ, Arap W, Pasqualini R. Mapping tumor vascular diversity by screening phage display libraries. J Control Release 2003 ; 91 (1-2): 183-186 (Pubitemid 37288889)
101. Scott JK, Smith GP. Searching for peptide ligands with an epitope library. Science 1990 ; 249 (4967): 386-390 (Pubitemid 20248864)
102. Christianson DR, Ozawa MG, Pasqualini R, Arap W. Techniques to decipher molecular diversity by phage display. Methods Mol Biol 2007 ; 357 : 385-406 (Pubitemid 350183263)
103. Koivunen E, Arap W, Rajotte D, et al. Identifi cation of receptor ligands with phage display peptide libraries. J Nucl Med 1999 ; 40 (5): 883-888 (Pubitemid 29210767)
104. Kolonin MG, Bover L, Sun J, et al. Ligand-directed surface profi ling of human cancer cells with combinatorial peptide libraries. Cancer Res 2006 ; 66 (1): 34-40 (Pubitemid 43166005)
105. Mintz PJ, Kim J, Do KA, et al. Fingerprinting the circulating repertoire of antibodies from cancer patients. Nat Biotechnol 2003 ; 21 (1): 57-63 (Pubitemid 36055828)
106. Oh Y, Mohiuddin I, Sun Y, et al. Phenotypic diversity of the lung vasculature in experimental models of metastases. Chest 2005 ; 128 (6 Suppl): 596S-600S (Pubitemid 43054147)
107. Trepel M, Arap W, Pasqualini R. In vivo phage display and vascular heterogeneity: implications for targeted medicine. Curr Opin Chem Biol 2002 ; 6 (3): 399-404
108. Pasqualini R, Ruoslahti E. Organ targeting in vivo using phage display peptide libraries. Nature 1996 ; 380 (6572): 364-366 (Pubitemid 26097120)
109. Arap W, Pasqualini R, Ruoslahti E. Chemotherapy targeted to tumor vasculature. Curr Opin Oncol 1998 ; 10 (6): 560-565 (Pubitemid 28502251)
110. Kolonin M, Pasqualini R, Arap W. Molecular addresses in blood vessels as targets for therapy. Curr Opin Chem Biol 2001 ; 5 (3): 308-313 (Pubitemid 32718528)
111. Pasqualini R, McDonald DM, Arap W. Vascular targeting and antigen presentation. Nat Immunol 2001 ; 2 (7): 567-568 (Pubitemid 32677617)
112. Pasqualini R, Arap W. Translation of vascular diversity into targeted therapeutics. Ann Hematol 2002 ; 81 (Suppl 2): S66 -7 (Pubitemid 36204351)
113. Hajitou A, Pasqualini R, Arap W. Vascular targeting: recent advances and therapeutic perspectives. Trends Cardiovasc Med 2006 ; 16 (3): 80-88
114. Ozawa MG, Zurita AJ, Dias-Neto E, et al. Beyond receptor expression levels: the relevance of target accessibility in ligand-directed pharmacodelivery systems. Trends Cardiovasc Med 2008 ; 18 (4): 126-132 (Pubitemid 351794541)
115. Marchiò S, Lahdenranta J, Schlingemann RO, et al. Aminopeptidase A is a functional target in angiogenic blood vessels. Cancer Cell 2004 ; 5 (2): 151-162 (Pubitemid 38283801)
116. Pasqualini R, Koivunen E, Kain R, et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res 2000 ; 60 (3): 722-727 (Pubitemid 30094573)
117. Pasqualini R, Koivunen E, Ruoslahti E. αv integrins as receptors for tumor targeting by circulating ligands. Nat Biotechnol 1997 ; 15 (6): 542-546 (Pubitemid 27251571)
118. Arap MA, Lahdenranta J, Mintz PJ, et al. Cell surface expression of the stress response chaperone GRP78 enables tumor targeting by circulating ligands. Cancer Cell 2004 ; 6 (3): 275-284 (Pubitemid 39222040)
119. Burg MA, Pasqualini R, Arap W, et al. NG2 proteoglycan-binding peptides target tumor neovasculature. Cancer Res 1999 ; 59 (12): 2869-2874 (Pubitemid 29283125)
120. Koivunen E, Restel BH, Rajotte D, et al. Integrin-binding peptides derived from phage display libraries. Methods Mol Biol 1999 ; 129 : 3-17
121. Christian S, Pilch J, Akerman ME, et al. Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels. J Cell Biol 2003 ; 163 (4): 871-878 (Pubitemid 37517893)
122. Laakkonen P, Porkka K, Hoffman JA, Ruoslahti E. A tumor-homing peptide with a targeting specifi city related to lymphatic vessels. Nat Med 2002 ; 8 (7): 751-755 (Pubitemid 34778730)
123. Zhang L, Giraudo E, Hoffman JA, et al. Lymphatic zip codes in premalignant lesions and tumors. Cancer Res 2006 ; 66 (11): 5696-5706 (Pubitemid 43927122)
124. Joyce JA, Laakkonen P, Bernasconi M, et al. Stage-specifi c vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. Cancer Cell 2003 ; 4 (5): 393-403 (Pubitemid 37491100)
125. Hoffman JA, Giraudo E, Singh M, et al. Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma. Cancer Cell 2003 ; 4 (5): 383-391 (Pubitemid 37491099)
126. Arap W, Kolonin MG, Trepel M, et al. Steps toward mapping the human vasculature by phage display. Nat Med 2002 ; 8 (2): 121-127 (Pubitemid 34155122)
127. Pentz RD, Cohen CB, Wicclair M, et al. Ethics guidelines for research with the recently dead. Nat Med 2005 ; 11 (11): 1145-1149 (Pubitemid 43093654)
128. Pentz RD, Flamm AL, Pasqualini R, et al. Revisiting ethical guidelines for research with terminal wean and brain-dead participants. Hastings Cent Rep 2003 ; 33 (1): 20-26
129. Zurita AJ, Troncoso P, Cardò-vila M, et al. Combinatorial screenings in patients: the interleukin-11 receptor α as a candidate target in the progression of human prostate cancer. Cancer Res 2004 ; 64 (2): 435-439 (Pubitemid 38120878)
130. Kolonin MG, Sun J, Do KA, et al. Synchronous selection of homing peptides for multiple tissues by in vivo phage display. Faseb J 2006 ; 20 (7): 979-981 (Pubitemid 44943923)
131. Arap W, Haedicke W, Bernasconi M, et al. Targeting the prostate for destruction through a vascular address. Proc Natl Acad Sci USA 2002 ; 99 (3): 1527-1531 (Pubitemid 34136526)
132. Ellerby HM, Arap W, Ellerby LM, et al. Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med 1999 ; 5 (9): 1032-1038 (Pubitemid 29439574)
133. Curnis F, Sacchi A, Borgna L, et al. Enhancement of tumor necrosis factor α antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol 2000 ; 18 (11): 1185-1190 (Pubitemid 30823358)
134. Hong FD, Clayman GL. Isolation of a peptide for targeted drug delivery into human head and neck solid tumors. Cancer Res 2000 ; 60 (23): 6551-6556
135. Cho K, Wang X, Nie S, et al. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 2008 ; 14 (5): 1310-1316
136. Saad M, Garbuzenko OB, Ber E, et al. Receptor targeted polymers, dendrimers, liposomes: which nanocarrier is the most effi cient for tumor-specifi c treatment and imaging? J Control Release 2008 ; 130 (2): 107-114
137. Bar H, Yacoby I, Benhar I. Killing cancer cells by targeted drug-carrying phage nanomedicines. BMC Biotechnol 2008 ; 8 : 37 . Published online April 3 2008, doi:10.1186/1472-6750-8-37 (Pubitemid 351566953)
138. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science 2004 ; 303 (5665): 1818-1822 (Pubitemid 38374867)
139. Gabizon A, Catane R, Uziely B, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994 ; 54 (4): 987-992 (Pubitemid 24085451)
140. Kontermann RE. Immunoliposomes for cancer therapy. Curr Opin Mol Ther 2006 ; 8 (1): 39-45 (Pubitemid 43230899)
141. Muggia FM, Hainsworth JD, Jeffers S, et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modifi cation by liposomal encapsulation. J Clin Oncol 1997 ; 15 (3): 987-993 (Pubitemid 27106281)
142. Northfelt DW, Martin FJ, Working P, et al. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J Clin Pharmacol 1996 ; 36 (1): 55-63 (Pubitemid 26058811)
143. Pastorino F, Brignole C, Di Paolo D, et al. Targeting liposomal chemotherapy via both tumor cell-specifi c and tumor vasculature-specifi c ligands potentiates therapeutic effi cacy. Cancer Res 2006 ; 66 (20): 10073-10082 (Pubitemid 44672061)
144. Lee TY, Lin CT, Kuo SY, et al. Peptide-mediated targeting to tumor blood vessels of lung cancer for drug delivery. Cancer Res 2007 ; 67 (22): 10958-10965
145. Hwang SH, Rait A, Pirollo KF, et al. Tumor-targeting nanodelivery enhances the anticancer activity of a novel quinazolinone analogue. Mol Cancer Ther 2008 ; 7 (3): 559-568
146. Souza GR, Christianson DR, Staquicini FI, et al. Networks of gold nanoparticles and bacteriophage as biological sensors and cell-targeting agents.
147. Souza GR, Levin CS, Hajitou A, et al. In vivo detection of gold-imidazole self-assembly complexes: NIR-SERS signal reporters. Anal Chem 2006 ; 78 (17): 6232-6237
148. Qian X, Peng XH, Ansari DO, et al. In vivo tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags. Nat Biotechnol 2008 ; 26 (1): 83-90
149. Swanson SD, Kukowska-Latallo JF, Patri AK, et al. Targeted gadolinium-loaded dendrimer nanoparticles for tumor-specifi c magnetic resonance contrast enhancement. Int J Nanomedicine 2008 ; 3 (2): 201-210 (Pubitemid 352037852)
150. Sun C, Fang C, Stephen Z, et al. Tumor-targeted drug delivery and MRI contrast enhancement by chlorotoxin-conjugated iron oxide nanoparticles. Nanomed 2008;3(4):495-505
151. Sagynaliev E, Steinert R, Nestler G, et al. Web-based data warehouse on gene expression in human colorectal cancer. Proteomics 2005 ; 5 (12): 3066-3078 (Pubitemid 41176473)
152. Pasqualini R, Arap W, McDonald DM. Probing the structural and molecular diversity of tumor vasculature. Trends Mol Med 2002 ; 8 (12): 563-571 (Pubitemid 35408214)
153. Abdollahi A, Lipson KE, Sckell A, et al. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects. Cancer Res 2003 ; 63 (24): 8890-8898 (Pubitemid 38064069)